PA
PTLA

Perceptive Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Perceptive Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-100,000
Closed -$158K – 156
2018
Q1 		$158K Buy
+100,000
New +$4.39M ﹤0.01% 134

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ZCI
Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Perceptive Advisors's PTLA Position: Q2 2018 in Review

Perceptive Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 440,000 shares — an estimated $14.4M sold.

Perceptive Advisors first reported a position in PTLA in Q4 2014 and held it in 7 quarters. The position peaked at $14.4M in Q1 2018. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

  • Perceptive Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Perceptive Advisors sold 440,000 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $14.4M.
  • Perceptive Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
  • Perceptive Advisors's Portola Pharmaceuticals, Inc. position peaked at $14.4M in Q1 2018.
  • 204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on Perceptive Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.